Consolidative high‐dose thoracic radiotherapy for limited metastatic nonsmall cell lung cancer: Focusing on oligo‐progressive disease
Authors:
- 4 December 2022
- journal article
- research article
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 19 (3) , 385-391
Abstract
AimPrior clinical data have shown a significant survival benefit of consolidative local radiotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC). Therefore, this study aimed to evaluate the impact of consolidative high-dose thoracic radiotherapy on local control rates and survivals in patients with limited metastatic NSCLC, especially focusing on oligo-progressive disease. MethodsWe retrospectively reviewed the medical records of 45 patients with limited metastatic NSCLC who received consolidative high-dose thoracic radiotherapy at the Korea University Guro Hospital between March 2015 and December 2020. In the current study, we included patients who showed partial response, stable disease, or oligo-progressive disease on tumor response evaluation after systemic treatment. All patients underwent stereotactic body radiation therapy (23 patients) or intensity-modulated radiation therapy (IMRT, 22 patients). ResultsThe median follow-up time was 42 months (range: 5-88 months). The overall 2-year disease-free survival (DFS) and overall survival (OS) rates were 80.7% and 88.4%, respectively. Among the 45 patients, only two patients treated with IMRT showed in-field local recurrence. There was no local failure among the patients who showed oligo-progressive disease after systemic treatment. In addition, the response to systemic treatment was not a significant factor for either DFS or OS rates (p = .471 and p = .414, respectively) in univariate analysis. ConclusionsConsolidative high-dose thoracic radiotherapy improves local control rates and helps achieve long-term survival in patients with limited metastatic NSCLC. It is also effective and should be considered in patients with oligo-progressive disease after systemic treatment.Keywords
This publication has 26 references indexed in Scilit:
- The oligometastatic state—separating truth from wishful thinkingNature Reviews Clinical Oncology, 2014
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR MutationsJournal of Clinical Oncology, 2013
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Stereotactic Body Radiation Therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancerStrahlentherapie und Onkologie, 2011
- Stereotactic Radiotherapy for Pulmonary Oligometastases: A Systematic ReviewJournal of Thoracic Oncology, 2010
- Radiotherapy and Radiosurgery for Metastatic Spine DiseaseSpine, 2009
- Stereotactic Body Radiotherapy for Treatment of Adrenal MetastasesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung MetastasesJournal of Clinical Oncology, 2009
- A prospective pilot study of curative‐intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesionsCancer, 2007
- Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii studyActa Oncologica, 2006